Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5‐anhydroglucitol (坎格列净，一种钠‐葡萄糖共转运体2抑制剂，对血清1,5‐脱水葡萄糖醇测定的影响)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

“…The level of serum 1,5‐anhydroglucitol (1,5‐AG) is believed to decrease in patients who received an SGLT2 inhibitor . A small number of studies demonstrated a strong positive correlation between serum UA and 1,5‐AG levels .…”

“…The level of serum 1,5-anhydroglucitol (1,5-AG) is believed to decrease in patients who received an SGLT2 inhibitor. 13 A small number of studies demonstrated a strong positive correlation between serum UA and 1,5-AG levels. [14][15][16] Yamanouchi et al and the authors of the present study have shown negative associations between urinary NAG (U/L) levels, 17 urinary NAG-creatinine ratio levels 18,19 and serum 1,5-AG.…”

Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters

“…[56][57][58] The limitation of this biomarker derives mainly from renal function and factors that influence the renal threshold to glucose. 59 1,5-AG has not been adequately studied in severe hyperglycemia and marked glycosuria (A1C >10%). 60 There are currently no guidelines of how often this biomarker should be obtained in clinical practice (Table 1).…”

Sodium Glucose Cotransporter 2 Inhibitors

“…When patients treated with canagliflozin were evaluated their 1,5-AG concentrations were lower than those observed in the placebo group. 35 These findings of low 1,5-AG concentrations were incongruent with the improved glycemic indices observed in the patients. The study concluded that there was interference with the 1,5-AG test when used in the context of SGLT2 inhibition.…”

“…35 Under usual conditions (without SGLT2 inhibition) of hyperglycemia there is an inverse relationship between mean glucose levels and 1,5-AG levels. High serum glucose levels result in significant glucose in the renal tubules.…”